From Pulse 2.0 · Amit Chowdhry · · 1m 50s
Isomorphic Labs Raises $5 Billion for AI Drug Discovery
Isomorphic Labs secures $5 billion Series C funding to accelerate AI-driven drug design and clinical trials.
In brief
Isomorphic Labs secures $5 billion Series C funding to accelerate AI-driven drug design and clinical trials. Isomorphic Labs raised $5 billion in Series C funding to advance AI drug discovery platforms and clinical candidates. Originally reported by Pulse 2.0.
Funding Round Details
Isomorphic Labs raised $5 billion in an oversubscribed Series C financing to expand its artificial intelligence drug-design platform and advance internally developed and partnered therapeutic candidates toward clinical trials.
Investors
Greenoaks and Sequoia Capital co-led the round. Andreessen Horowitz and several other new investors also participated, while Alphabet made an additional significant investment.
Existing Investors
All existing investors joined the financing, including Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund.
Use of Funds
Isomorphic Labs will use the capital to develop additional foundational AI models, expand its drug pipeline, build translational and clinical development capabilities, and establish global infrastructure for AI-led bioengineering.
IsoDDE Platform
Isomorphic Labs has developed a proprietary drug-design system called IsoDDE that combines foundational simulation models across multiple therapeutic areas and types of medicines.
Drug Design Process
The platform helps researchers explore large chemical spaces, design molecules, and optimize characteristics relevant to potential drugs while balancing stability, tissue reach, and manufacturing suitability.
Oncology and Immunology Programs
Isomorphic Labs is building a multi-modality pipeline covering oncology and immunology with positive preclinical results preparing for clinical development.
Clinical Transition Infrastructure
The new funding supports translational research, manufacturing preparation, regulatory work, and clinical development programs to transition candidates into clinical trials.
Foundational Biology Models
Isomorphic plans to expand into additional areas of biology by building foundational models for molecular-level biological systems and a partner ecosystem for mechanistic disease biology.
The one thing
Isomorphic Labs raised $5 billion in Series C funding to advance AI drug discovery platforms and clinical candidates.
Read the TL;DR — this story on one card.





